In addition, the BCR-ABL1 transcript level is currently a key predictive biomarker of CML response to treatment with Tyrosine Kinase Inhibitors (TKIs). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.